Relmada Therapeutics, Inc. RLMD Preferred Stock, Shares Authorized
Preferred Stock, Shares Authorized at other companies
Other financials
Where this comes from
Reported directly by Relmada Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:PreferredStockSharesAuthorized.
The official record: Relmada Therapeutics, Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →
Ask your AI about Relmada Therapeutics, Inc.'s preferred stock, shares authorized.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Relmada Therapeutics, Inc.'s preferred stock, shares authorized?
- Relmada Therapeutics, Inc. (RLMD) reported preferred stock, shares authorized of $200M in Q1 2026.
- How has Relmada Therapeutics, Inc.'s preferred stock, shares authorized changed year-over-year?
- Relmada Therapeutics, Inc.'s preferred stock, shares authorized decreased by 0.0% year-over-year, from $200M to $200M.
- What is the long-term trend for Relmada Therapeutics, Inc.'s preferred stock, shares authorized?
- Over 5 years (2020 to 2025), Relmada Therapeutics, Inc.'s preferred stock, shares authorized has grown at a 0.0% compound annual growth rate (CAGR), from $200M to $200M.